Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial

9/29 Late treatment study

Dabbous et al., Scientific Reports, doi:10.1038/s41598-021-85227-0 (preprint 9/29/20) (Peer Reviewed)
Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial

Source PDF Share Tweet

Small RCT comparing HCQ and favipiravir, with 50 patients in each arm, finding that 55.1% of HCQ patients were PCR negative on day 7 compared to 48% for favipiravir, p = 0.7. There was no comparison with a control group. NCT04349241.

Dabbous et al., 9/29/2020, peer-reviewed, 11 authors.

All 344 studies Meta Analysis

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit